Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Relativ biotilgængelighed af en enkelt oral dosis af BI 425809, når den administreres alene eller i kombination med flere orale doser af itraconazol hos raske mandlige forsøgspersoner

9. juli 2026 opdateret af: Boehringer Ingelheim

Relativ biotilgængelighed af en enkelt oral dosis af BI 425809, når den administreres alene eller i kombination med flere orale doser af itraconazol hos raske mandlige forsøgspersoner (et åbent, to-perioders forsøg med fast sekvens)

To investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI 425809 in healthy male subjects

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

16

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Biberach, Tyskland
        • 1346.10.1 Boehringer Ingelheim Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 50 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion criteria:

  • Healthy male subjects according to the investigator's assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
  • Age of 18 to 50 years (incl.)
  • Body mass index (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria:

  • Any finding in the medical examination (including BP, PR or ECG) is deviating from normal and judged as clinically relevant by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
  • Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 halflives of the respective drug prior to administration of trial medication
  • Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial or that might prolong the QT/QTc interval
  • Participation in another trial where an investigational drug has been administered within 60 days prior to planned administration of trial medication
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  • Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until two month after the trial completion. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive for at least two month prior trial participation)
  • Known fructose intolerance, glucose-galactose malabsorption, or saccharose-isomaltase deficiency
  • History of relevant liver diseases such as disturbance of liver function, jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver tumours
  • Liver enzymes (ALT, AST, GGT) above upper limit of normal at the screening examination

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment R (BI 425809 alone) then Treatment T (BI 425809 + Itraconazole)

Treatment R: Subjects were administered single dose of 25 milligram (mg) BI 425809 (tablet) on Day 1.

Treatment was administered orally with 240 mL of water after administration of a standardised breakfast. Treatment T: Subjects underwent 10 days of itraconazole (capsules) treatment (first day 200 mg itraconazole twice daily, followed by 9 days 200 mg itraconazole once daily) combined with a single dose of 25 mg BI 425809 (tablet) on the fourth day of the itraconazole treatment (1 h after the itraconazole administration).

Treatments were administered orally with 240 mL of water after administration of a standardised breakfast or dinner. The BI 425809 single doses of treatments R and T were separated by a washout period of at least 16 days.

single dose BI 425809 tablet

Andre navne:
  • Iclepertin

multiple doses of Itraconazole capsules

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to 167 h (AUC0-167)
Tidsramme: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

AUC0-167 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 167 h);

Detailed sampling time points:

-2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration

Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.
Maximum Measured Concentration of BI 425809 in Plasma (Cmax)
Tidsramme: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

Cmax (maximum measured concentration of the analyte in plasma);

Detailed sampling time points:

-2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h and 191h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h, 191h, 239h, 287h and 335h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration

Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Tidsramme: Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity);

Detailed sampling time points:

-2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h and 191h after Treatment R (BI 425809 single dose) administration; -2 hours (h), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h, 95h, 119h, 143h, 167h, 191h, 239h, 287h and 335h after Treatment T (Itraconazole multiple dose + BI 425809 single dose) administration

Treatment R: -2h predose on Day 1 of the reference period up to 167h postdose; Treatment T: -2h predose on Day 1 of this period up to 167h postdose (Treatment T occurred at least 16 days after Treatment R). See description for sampling timepoints.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studiestol: Boehringer Ingelheim, Boehringer Ingelheim

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. januar 2015

Primær færdiggørelse (Faktiske)

24. marts 2015

Studieafslutning (Faktiske)

24. marts 2015

Datoer for studieregistrering

Først indsendt

15. januar 2015

Først indsendt, der opfyldte QC-kriterier

15. januar 2015

Først opslået (Anslået)

21. januar 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 1346.10
  • 2014-004855-29 (EudraCT nummer: EudraCT)
  • 2014 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases(in case of low number of patients and therefore limitations with anonymization).

For more details refer to:

https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner